MicroRNas: master regulators of drug resistance, stemness and metastasis

dc.citation.epage336en_US
dc.citation.issueNumber4en_US
dc.citation.spage321en_US
dc.citation.volumeNumber92en_US
dc.contributor.authorRaza, U.en_US
dc.contributor.authorZhang, J. D.en_US
dc.contributor.authorŞahin, Ö.en_US
dc.date.accessioned2015-07-28T12:03:36Z
dc.date.available2015-07-28T12:03:36Z
dc.date.issued2014-04en_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractMicroRNAs (miRNAs) are 20-22 nucleotides long small non-coding RNAs that regulate gene expression post-transcriptionally. Last decade has witnessed emerging evidences of active roles of miRNAs in tumor development, progression, metastasis, and drug resistance. Many factors contribute to their dysregulation in cancer, such as chromosomal aberrations, differential methylation of their own or host genes' promoters and alterations in miRNA biogenesis pathways. miRNAs have been shown to act as tumor suppressors or oncogenes depending on the targets they regulate and the tissue where they are expressed. Because miRNAs can regulate dozens of genes simultaneously and they can function as tumor suppressors or oncogenes, they have been proposed as promising targets for cancer therapy. In this review, we focus on the role of miRNAs in driving drug resistance and metastasis which are associated with stem cell properties of cancer cells. Furthermore, we discuss systems biology approaches to combine experimental and computational methods to study effects of miRNAs on gene or protein networks regulating these processes. Finally, we describe methods to target oncogenic or replace tumor suppressor miRNAs and current delivery strategies to sensitize refractory cells and to prevent metastasis. A holistic understanding of miRNAs' functions in drug resistance and metastasis, which are major causes of cancer-related deaths, and the development of novel strategies to target them efficiently will pave the way towards better translation of miRNAs into clinics and management of cancer therapy. © 2014 Springer-Verlag Berlin Heidelberg.en_US
dc.description.provenanceMade available in DSpace on 2015-07-28T12:03:36Z (GMT). No. of bitstreams: 1 7280.pdf: 1208543 bytes, checksum: 9b899a211aa793ffe8f74dd75a3d4ad3 (MD5)en
dc.identifier.doi10.1007/s00109-014-1129-2en_US
dc.identifier.issn0946-2716
dc.identifier.urihttp://hdl.handle.net/11693/12872
dc.language.isoEnglishen_US
dc.publisherSpringer Berlin Heidelbergen_US
dc.relation.isversionofhttp://dx.doi.org/10.1007/s00109-014-1129-2en_US
dc.source.titleJournal of Molecular Medicineen_US
dc.subjectDrug resistanceen_US
dc.subjectEpithelial-mesenchymal transitionen_US
dc.subjectMetastasisen_US
dc.subjectMicrornasen_US
dc.subjectMirna-protein interaction networksen_US
dc.subjectStemnessen_US
dc.subjectSystems biomedicineen_US
dc.titleMicroRNas: master regulators of drug resistance, stemness and metastasisen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
7280.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Description:
Full printable version